Home / People / Niall McAlister
Portrait of Niall McAlister

Niall McAlister


CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Niall McAlister is a partner in the Corporate/M&A Team at CMS London. With over thirty years' experience as a corporate lawyer, Niall has particular expertise in mergers and acquisitions, joint ventures and private equity and venture capital transactions.  He has a particular focus on the Life Sciences & Healthcare sector. He has led teams on a number of substantial cross-border transactions. He is experienced in representing life sciences clients, having advised both commercial entities and medical research charities on a range of transactions in the sector. He is recognised in directories for his expertise both as a corporate lawyer in the life sciences sector and as a charity lawyer. 

more less

"Recommended for transactions and venture capital investments in the life science sector."

Legal 500

Relevant experience

  • The owners of Aspine Pharma on the buy-out of the company to HIG Capital.
  • Contura Holdings on the sale of its women's health business to Axonics Modulation Technologies for up to USD 230m.
  • The owners of iPlato on its sale to Huma Therapeutics.
  • The owners of Sirakoss on the sale of the company to OssDsign.
  • Syncona on the sale of Blue Earth Diagnostics to Bracco Imaging for $450m.
  • The owners of a generic therapeutics business on its sale to a private equity purchaser.
  • The owners of Birken AG on its sale to Amryt Pharmaceuticals.
  • The managers of Speciality European Pharmaceuticals on the management buy-out of the company from a consortium of investors led by Advent Partners.
  • A leading biologics developer on a substantial joint venture with a global pharmaceutical company to develop a biosimilar to a "blockbuster" therapeutic.
  • The owners of Antitope on the sale of the company to PolyTherics.
  • The owners of Luminescence, a manufacturer of high-quality security inks, on the sale of the company to Sun Chemicals.
  • The owners of a speciality pharmaceuticals and medical device business on a three-way demerger of the business.
  • Integra Lifesciences on various reorganisations of its European business.
  • Gyroscope Therapeutics on its Series B investment round.
  • Epidarex Capital on a range of early-stage investments including in Lazo Therapeutics, Kynos Therapeutics, Theolytics, Dunad Therapeutics, Curve Therapeutics, Mironid, Leucid Bio, Lunac Therapeutics, EM Imaging, Enterprise Therapeutics and Topas Therapeutics.
  • ALSA Holdings and Albion Capital on their Series A investment in iGem Therapeutics.
  • SR One and Longwood Fund on their investment in Pulmocide.
  • Astellas Venture Managers on its investments in F2G, Bicycle Therapeutics and Crescendo Biologics.
  • The Wellcome Trust on a number of venture capital investments in European biotech and medical device companies.
  • A number of early-stage companies, including AdoRx Pharmaceuticals, Nugeronlix, Lunac Therapeutics, Sirahoss and Michelson Diagnostics, on investment rounds.
  • A major international pharmaceutical company on its auction bid for a substantial European pharmaceutical business.
  • A client on European aspects of the buy-out of a global medical imaging business and on the subsequent group restructuring.
  • Astex Therapeutics on its investment into the Dementia Discovery Fund, a limited partnership established to develop therapies for dementia and related conditions.
  • UKCMRI Limited on its negotiation of the joint venture with the MRC, Cancer Research UK, the Wellcome Trust and Imperial College London to create the Crick Institute.
  • The Wellcome Trust on its joint venture with GSK to develop the Stevenage Bioscience Incubator.
more less


  • 1986 – LL.B., University of Bristol, Bristol
more less


CMS Ex­pert Guide to di­git­al health apps and telemedi­cine
Fu­ture fa­cing Di­git­isa­tion is ad­van­cing stead­ily. Its pi­on­eer­ing in­nov­a­tions chal­lenge all parties in­volved. One of the most im­port­ant as­pects in this area is the huge po­ten­tial that lies in the di­git­isa­tion...
AI in Life Sci­ences
Ar­ti­fi­cial in­tel­li­gence is not new: the term it­self was coined over 60 years ago. However, the con­ver­gence of data volume, pro­cessing power and tech­nic­al cap­ab­il­ity has con­vinced many that the AI era...
CMS ad­vises sellers in re­la­tion to $450m sale of Blue Earth Dia­gnostics
In­ter­na­tion­al law firm CMS has ad­vised the sellers in re­la­tion to the sale of Blue Earth Dia­gnostics to dia­gnost­ic ima­ging busi­ness Bracco Ima­ging.Bracco Ima­ging will ac­quire all out­stand­ing shares of...
Launch of Life Sci­ences Sec­tor Deal 2
The In­dus­tri­al Strategy – Life Sci­ences Sec­tor Deal 2 re­port is broken down by themes with each identi­fy­ing what pro­gress has been made by each of the sec­tor and Gov­ern­ment. A sum­mary of these themes...
Trans­form­ing health and so­cial care
In­dustry per­spect­ives on the op­por­tun­it­ies and chal­lenges of AI At a roundtable event in Lon­don in Septem­ber 2018, CMS as­sembled a se­lec­tion of health­care op­er­at­ors, in­dustry ex­perts, healthtech com­pan­ies...
Olswang ad­vises two new VC cli­ents on Series B in­vest­ment round in Brit­ish...
This art­icle was pro­duced by Olswang LLP, which joined with CMS on 1 May 2017.In­ter­na­tion­al tech­no­logy, me­dia and tele­coms law firm Olswang has ad­vised ven­ture cap­it­al firms SR One Ltd and Long­wood Fund...
Olswang boosts Life Sci­ences of­fer­ing with new cor­por­ate part­ner
This art­icle was pro­duced by Olswang LLP, which joined CMS on 1 May 2017.In­ter­na­tion­al law firm Olswang has an­nounced that Ni­all Mc­Al­ister joined the firm on 29 Septem­ber as a cor­por­ate part­ner in its...